QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The ...
Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed withour AI-Immunology™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback